PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31645440-2	2020	LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	17-20
34837846-9	2022	MEK inhibitor showed synergy with multikinase inhibitor ponatinib, ABL inhibitor nilotinib, PI3K/mTOR inhibitor pictilisib, and pan-RAF inhibitor LY3009120.	LY3009120	146-155	mitogen-activated protein kinase kinase 7	Homo sapiens	0-3
34837846-9	2022	MEK inhibitor showed synergy with multikinase inhibitor ponatinib, ABL inhibitor nilotinib, PI3K/mTOR inhibitor pictilisib, and pan-RAF inhibitor LY3009120.	LY3009120	146-155	zinc fingers and homeoboxes 2	Homo sapiens	132-135
34298678-5	2021	Using the RAF inhibitor LY3009120, we show that RAF activity determines the sensitivity of leukemic cells toward hydroxyurea.	LY3009120	24-33	zinc fingers and homeoboxes 2	Homo sapiens	10-13
34298678-5	2021	Using the RAF inhibitor LY3009120, we show that RAF activity determines the sensitivity of leukemic cells toward hydroxyurea.	LY3009120	24-33	zinc fingers and homeoboxes 2	Homo sapiens	48-51
33255818-3	2020	LY3009120 had anti-proliferative and pro-apoptotic effects and suppressed pERK1/2 levels in leukemic cells with RAS and FLT3 mutations.	LY3009120	0-9	fms related receptor tyrosine kinase 3	Homo sapiens	120-124
33255818-6	2020	Furthermore, the combination of LY3009120 and sorafenib resulted in significantly higher levels of apoptosis in AML cells with heterozygous and hemizygous FLT3 mutations.	LY3009120	32-41	fms related receptor tyrosine kinase 3	Homo sapiens	155-159
33255818-7	2020	In conclusion, pan-RAF inhibition in AML using LY3009120 results in anti-leukemic activity, and combination with Ara-C or sorafenib potentiates its effect.	LY3009120	47-56	zinc fingers and homeoboxes 2	Homo sapiens	19-22
32366411-0	2020	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.	LY3009120	39-48	zinc fingers and homeoboxes 2	Homo sapiens	25-28
32366411-0	2020	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.	LY3009120	39-48	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	95-99
32366411-2	2020	LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	34-37
32366411-2	2020	LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	108-112
32366411-7	2020	RESULTS: LY3009120 suppressed BRAF-related downstream pathway molecules and induced cleavage of poly ADP-ribose polymerase in all examined NSCLC cell lines.	LY3009120	9-18	Braf transforming gene	Mus musculus	30-34
32366411-7	2020	RESULTS: LY3009120 suppressed BRAF-related downstream pathway molecules and induced cleavage of poly ADP-ribose polymerase in all examined NSCLC cell lines.	LY3009120	9-18	poly(ADP-ribose) polymerase 1	Homo sapiens	96-122
32366411-8	2020	LY3009120 also inhibited in vivo tumor growth in NSCLC cells harboring the BRAF non-V600E mutation.	LY3009120	0-9	Braf transforming gene	Mus musculus	75-79
32366411-9	2020	CONCLUSION: LY3009120 is a potent therapeutic agent for patients with BRAF non-V600E mutant NSCLC.	LY3009120	12-21	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	70-74
34539849-0	2021	Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations.	LY3009120	18-27	zinc fingers and homeoboxes 2	Homo sapiens	4-7
34539849-4	2021	We found that LY3009120, a pan-RAF inhibitor, significantly decreased cell survival in RAS-mutated AML cell lines.	LY3009120	14-23	zinc fingers and homeoboxes 2	Homo sapiens	31-34
34539849-6	2021	We found that the combination of low-dose cytarabine and LY3009120 showed a synergistic effect in NRAS-mutated HL-60 cells and KRAS-mutated NB4 cells.	LY3009120	57-66	NRAS proto-oncogene, GTPase	Homo sapiens	98-102
34539849-6	2021	We found that the combination of low-dose cytarabine and LY3009120 showed a synergistic effect in NRAS-mutated HL-60 cells and KRAS-mutated NB4 cells.	LY3009120	57-66	KRAS proto-oncogene, GTPase	Homo sapiens	127-131
34539849-7	2021	This effect was caused by a decrease in proliferation, induction of apoptosis, and cell growth arrest through a decrease in phosphorylated MEK and ERK along with a cytotoxic response occurring specifically for the RAS mutation of the pan-RAF inhibitor LY3009120.	LY3009120	252-261	mitogen-activated protein kinase kinase 7	Homo sapiens	139-142
34539849-7	2021	This effect was caused by a decrease in proliferation, induction of apoptosis, and cell growth arrest through a decrease in phosphorylated MEK and ERK along with a cytotoxic response occurring specifically for the RAS mutation of the pan-RAF inhibitor LY3009120.	LY3009120	252-261	zinc fingers and homeoboxes 2	Homo sapiens	238-241
34539849-9	2021	Our findings indicate that combination therapy with pan-RAF inhibitor LY3009120 and low-dose cytarabine may be a promising treatment strategy for RAS-mutated AML.	LY3009120	70-79	zinc fingers and homeoboxes 2	Homo sapiens	56-59
34667152-7	2021	Further, we found that TM7SF2 participated in promoting tumorigenesis and progression via activation of C-Raf/ERK pathway in cervical cancer, which can be partly reversed by Raf inhibitor LY3009120.	LY3009120	188-197	transmembrane 7 superfamily member 2	Mus musculus	23-29
34667152-7	2021	Further, we found that TM7SF2 participated in promoting tumorigenesis and progression via activation of C-Raf/ERK pathway in cervical cancer, which can be partly reversed by Raf inhibitor LY3009120.	LY3009120	188-197	v-raf-leukemia viral oncogene 1	Mus musculus	104-109
34667152-7	2021	Further, we found that TM7SF2 participated in promoting tumorigenesis and progression via activation of C-Raf/ERK pathway in cervical cancer, which can be partly reversed by Raf inhibitor LY3009120.	LY3009120	188-197	mitogen-activated protein kinase 1	Mus musculus	110-113
34667152-7	2021	Further, we found that TM7SF2 participated in promoting tumorigenesis and progression via activation of C-Raf/ERK pathway in cervical cancer, which can be partly reversed by Raf inhibitor LY3009120.	LY3009120	188-197	v-raf-leukemia viral oncogene 1	Mus musculus	174-177
35091470-3	2022	In this study, we showed that LY3009120, a pan-RAF inhibitor, can unexpectedly cause paradoxical ERK activation in KRASG12C-dependent lung cancer cell lines, when KRAS is inhibited by ARS1620, a KRASG12C inhibitor.	LY3009120	30-39	zinc fingers and homeoboxes 2	Mus musculus	47-50
35091470-3	2022	In this study, we showed that LY3009120, a pan-RAF inhibitor, can unexpectedly cause paradoxical ERK activation in KRASG12C-dependent lung cancer cell lines, when KRAS is inhibited by ARS1620, a KRASG12C inhibitor.	LY3009120	30-39	mitogen-activated protein kinase 1	Mus musculus	97-100
35091470-3	2022	In this study, we showed that LY3009120, a pan-RAF inhibitor, can unexpectedly cause paradoxical ERK activation in KRASG12C-dependent lung cancer cell lines, when KRAS is inhibited by ARS1620, a KRASG12C inhibitor.	LY3009120	30-39	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	163-167
34011980-11	2021	A combination treatment of a pan-RAF inhibitor (LY3009120) and a MEK inhibitor (trametinib) effectively suppressed phospho-ERK and inhibited growth of OCIP256 XDO and PDX models.	LY3009120	48-57	zinc fingers and homeoboxes 2	Homo sapiens	33-36
31645440-2	2020	LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	79-83
31645440-2	2020	LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	113-117
31645440-2	2020	LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	113-117
30622172-6	2019	In vitro studies using transfected Madin-Darby canine kidney II cells indicate that only LY3009120 and MLN2480 are substrates of Bcrp, and none of the three inhibitors are substrates of P-gp.	LY3009120	89-98	ATP binding cassette subfamily G member 2	Canis lupus familiaris	129-133
30944150-0	2019	A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis.	LY3009120	20-29	zinc fingers and homeoboxes 2	Mus musculus	6-9
30944150-0	2019	A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis.	LY3009120	20-29	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	84-89
30944150-4	2019	Through screening a clinical compound library that contains 611 inhibitors, a pan-RAF inhibitor LY3009120 was found to be promising as a necroptosis inhibitor.	LY3009120	96-105	zinc fingers and homeoboxes 2	Mus musculus	82-85
30944150-6	2019	Surprisingly, LY3009120 prevented phosphorylation of receptor interacting serine/threonine kinase 1 (RIPK1) and subsequently phosphorylation of receptor interacting serine/threonine kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) which happened during necroptosis.	LY3009120	14-23	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	101-106
30944150-6	2019	Surprisingly, LY3009120 prevented phosphorylation of receptor interacting serine/threonine kinase 1 (RIPK1) and subsequently phosphorylation of receptor interacting serine/threonine kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) which happened during necroptosis.	LY3009120	14-23	receptor-interacting serine-threonine kinase 3	Mus musculus	192-197
30944150-6	2019	Surprisingly, LY3009120 prevented phosphorylation of receptor interacting serine/threonine kinase 1 (RIPK1) and subsequently phosphorylation of receptor interacting serine/threonine kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) which happened during necroptosis.	LY3009120	14-23	mixed lineage kinase domain-like	Mus musculus	203-248
30944150-6	2019	Surprisingly, LY3009120 prevented phosphorylation of receptor interacting serine/threonine kinase 1 (RIPK1) and subsequently phosphorylation of receptor interacting serine/threonine kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) which happened during necroptosis.	LY3009120	14-23	mixed lineage kinase domain-like	Mus musculus	250-254
30944150-9	2019	Consistently, LY3009120 decreased DSS-induced colonic inflammation, as indicated by decreased infiltration of macrophages and neutrophils, and decreased colonic TNF-alpha, IL-6, and IL-1beta level in DSS treated mice.	LY3009120	14-23	interleukin 6	Mus musculus	172-176
30944150-9	2019	Consistently, LY3009120 decreased DSS-induced colonic inflammation, as indicated by decreased infiltration of macrophages and neutrophils, and decreased colonic TNF-alpha, IL-6, and IL-1beta level in DSS treated mice.	LY3009120	14-23	interleukin 1 alpha	Mus musculus	182-190
30944150-10	2019	These results indicate that an anti-cancer pan-RAF inhibitor LY3009120 is a necroptosis inhibitor and may serve as a potential therapeutic drug for colitis.	LY3009120	61-70	zinc fingers and homeoboxes 2	Mus musculus	47-50
30622172-8	2019	In vivo studies in mice show that the brain distribution of CCT196969, LY3009120, and MLN2480 is limited, and is enhanced in transgenic mice lacking P-gp and Bcrp.	LY3009120	71-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-162
30272260-0	2018	LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	0-9	zinc fingers and homeoboxes 2	Mus musculus	17-20
30517658-10	2019	Although first- and second-generation RAF inhibitors are predicted to be ineffective, this fusion may be targetable by the novel RAF inhibitor LY3009120 and to some extent by the MEK inhibitor trametinib.	LY3009120	143-152	zinc fingers and homeoboxes 2	Homo sapiens	129-132
30272260-0	2018	LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	0-9	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	130-141
30272260-0	2018	LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	0-9	peroxisome proliferator activated receptor gamma	Mus musculus	143-153
30272260-0	2018	LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	0-9	signal transducer and activator of transcription 3	Mus musculus	155-161
30272260-0	2018	LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	0-9	fatty acid synthase	Mus musculus	163-166
30272260-0	2018	LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	0-9	perilipin 1	Mus musculus	173-184
30272260-2	2018	LY3009120 is a pan-Raf kinase inhibitor and is known for its anticancer activities.	LY3009120	0-9	zinc fingers and homeoboxes 2	Mus musculus	19-22
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	45-81
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	83-94
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	peroxisome proliferator activated receptor gamma	Mus musculus	97-145
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	peroxisome proliferator activated receptor gamma	Mus musculus	147-157
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	fatty acid synthase	Mus musculus	160-179
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	fatty acid synthase	Mus musculus	181-184
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	perilipin 1	Mus musculus	221-232
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	signal transducer and activator of transcription 3	Mus musculus	274-324
30272260-9	2018	LY3009120 reduced not only the expression of CCAAT/enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and perilipin A, but also reduced the phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in differentiating 3T3-L1 cells.	LY3009120	0-9	signal transducer and activator of transcription 3	Mus musculus	326-332
30272260-11	2018	In summary, this is the first report, to the best of our knowledge, demonstrating that LY3009120 has an anti-adipogenic effect on 3T3-L1 cells, which may be mediated through control of the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	87-96	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	223-234
30272260-11	2018	In summary, this is the first report, to the best of our knowledge, demonstrating that LY3009120 has an anti-adipogenic effect on 3T3-L1 cells, which may be mediated through control of the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	87-96	peroxisome proliferator activated receptor gamma	Mus musculus	236-246
30272260-11	2018	In summary, this is the first report, to the best of our knowledge, demonstrating that LY3009120 has an anti-adipogenic effect on 3T3-L1 cells, which may be mediated through control of the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	87-96	signal transducer and activator of transcription 3	Mus musculus	248-254
30272260-11	2018	In summary, this is the first report, to the best of our knowledge, demonstrating that LY3009120 has an anti-adipogenic effect on 3T3-L1 cells, which may be mediated through control of the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	87-96	fatty acid synthase	Mus musculus	256-259
30272260-11	2018	In summary, this is the first report, to the best of our knowledge, demonstrating that LY3009120 has an anti-adipogenic effect on 3T3-L1 cells, which may be mediated through control of the expression and phosphorylation of C/EBP-alpha, PPAR-gamma, STAT-3, FAS, ACC, perilipin A, and AMPK.	LY3009120	87-96	perilipin 1	Mus musculus	266-277
29059158-0	2018	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.	LY3009120	14-23	zinc fingers and homeoboxes 2	Homo sapiens	0-3
30118796-18	2018	LY3009120 and lifirafenib, which are in the early drug-development stage, bind to a different inactive form of B-Raf (DFG-Dout) and are classified as type II inhibitors.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	111-116
29059158-0	2018	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.	LY3009120	14-23	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	42-46
29059158-0	2018	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.	LY3009120	14-23	cyclin dependent kinase 4	Homo sapiens	64-70
29059158-0	2018	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.	LY3009120	14-23	cyclin D1	Homo sapiens	154-163
29059158-3	2018	LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	17-20
29059158-3	2018	LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	25-28
29059158-3	2018	LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	111-115
29059158-5	2018	In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination.	LY3009120	56-65	KRAS proto-oncogene, GTPase	Homo sapiens	208-212
29059158-5	2018	In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination.	LY3009120	56-65	NRAS proto-oncogene, GTPase	Homo sapiens	214-218
29059158-5	2018	In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination.	LY3009120	56-65	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	222-226
29059158-8	2018	The combinatory treatment cooperatively demonstrated more complete inhibition of Rb phosphorylation, and LY3009120 suppressed the cyclin D1 upregulation mediated by abemaciclib.	LY3009120	105-114	cyclin D1	Homo sapiens	130-139
29059158-10	2018	Importantly, the more complete phospho-Rb inhibition and cyclin D1 suppression by LY3009120 and abemaciclib combination led to more significant cell cycle G0/G1 arrest of tumor cells.	LY3009120	82-91	cyclin D1	Homo sapiens	57-66
28576749-3	2017	Because selective BRAF inhibitors paradoxically induce downstream signaling activation, a pan-RAF inhibitor, LY3009120 is a better alternate for KRAS-mutant tumor treatment.	LY3009120	109-118	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	18-22
28806393-8	2017	The pan-RAF dimer inhibitor, LY3009120, could suppress CRAF-fusion oncogenicity by inhibiting dimer-mediated signaling.	LY3009120	29-38	zinc fingers and homeoboxes 2	Homo sapiens	8-11
28806393-8	2017	The pan-RAF dimer inhibitor, LY3009120, could suppress CRAF-fusion oncogenicity by inhibiting dimer-mediated signaling.	LY3009120	29-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	55-59
28576749-7	2017	In addition, LY3009120 exhibited a dramatically enhanced antitumor effect in combination with YAP knockdown.	LY3009120	13-22	Yes1 associated transcriptional regulator	Homo sapiens	94-97
28576749-8	2017	YAP depletion blocks the activation of a parallel AKT signal pathway after LY3009120 treatment.	LY3009120	75-84	Yes1 associated transcriptional regulator	Homo sapiens	0-3
28576749-9	2017	Finally, combination with a YAP inhibitor, verteporfin, significantly enhanced the antitumor efficacy of LY3009120.	LY3009120	105-114	Yes1 associated transcriptional regulator	Homo sapiens	28-31
28576749-10	2017	Collectively, our results demonstrate that genetic or pharmacological inhibition of YAP can increase sensitivity to LY3009120 in pancreatic cancer through blocking compensatory activation of a parallel AKT signal pathway, thereby validating a combinatorial approach for treating KRAS-mutant pancreatic cancer.	LY3009120	116-125	Yes1 associated transcriptional regulator	Homo sapiens	84-87
28382170-5	2017	LY3009120, the newly discovered pan-RAF inhibitor, successfully overcame Vemurafenib resistance and suppressed the growth of DTC cells in vitro and in vivo.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	36-39
26732095-0	2016	Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.	LY3009120	108-117	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	10-14
27999210-0	2017	LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	70-74
27999210-0	2017	LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.	LY3009120	0-9	KRAS proto-oncogene, GTPase	Homo sapiens	79-83
27999210-7	2017	The anti-proliferative effects of LY3009120 in KRASmut CRC cell lines phenocopied molecular inhibition of RAF isoforms by simultaneous siRNA-mediated knockdown of ARAF, BRAF and CRAF.	LY3009120	34-43	zinc fingers and homeoboxes 2	Homo sapiens	106-109
27999210-7	2017	The anti-proliferative effects of LY3009120 in KRASmut CRC cell lines phenocopied molecular inhibition of RAF isoforms by simultaneous siRNA-mediated knockdown of ARAF, BRAF and CRAF.	LY3009120	34-43	A-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	163-167
27999210-7	2017	The anti-proliferative effects of LY3009120 in KRASmut CRC cell lines phenocopied molecular inhibition of RAF isoforms by simultaneous siRNA-mediated knockdown of ARAF, BRAF and CRAF.	LY3009120	34-43	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	178-182
27999210-9	2017	Examination of potential resistance to LY3009120 demonstrated RAF-independent ERK and AKT activation in the KRASmut CRC cell line HCT 116.	LY3009120	39-48	zinc fingers and homeoboxes 2	Homo sapiens	62-65
27999210-9	2017	Examination of potential resistance to LY3009120 demonstrated RAF-independent ERK and AKT activation in the KRASmut CRC cell line HCT 116.	LY3009120	39-48	mitogen-activated protein kinase 1	Homo sapiens	78-81
27999210-9	2017	Examination of potential resistance to LY3009120 demonstrated RAF-independent ERK and AKT activation in the KRASmut CRC cell line HCT 116.	LY3009120	39-48	AKT serine/threonine kinase 1	Homo sapiens	86-89
28382170-6	2017	We also observed that expression of anti-apoptotic Bcl-2 increased substantially following BRAF inhibitor treatment in Vemurafenib-resistant K1 cells, and both Obatoclax and LY3009120 efficiently induced apoptosis of these resistant cells.	LY3009120	174-183	BCL2 apoptosis regulator	Homo sapiens	51-56
28382170-6	2017	We also observed that expression of anti-apoptotic Bcl-2 increased substantially following BRAF inhibitor treatment in Vemurafenib-resistant K1 cells, and both Obatoclax and LY3009120 efficiently induced apoptosis of these resistant cells.	LY3009120	174-183	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	91-95
26732095-0	2016	Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.	LY3009120	108-117	zinc fingers and homeoboxes 2	Homo sapiens	11-14
26732095-6	2016	BRAF homodimer is confirmed to be the dominant RAF dimer by proximity ligation assays in BRAF deletion cells, which are resistant to the BRAF inhibitor vemurafenib and sensitive to LY3009120, a RAF dimer inhibitor.	LY3009120	181-190	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	0-4
26732095-6	2016	BRAF homodimer is confirmed to be the dominant RAF dimer by proximity ligation assays in BRAF deletion cells, which are resistant to the BRAF inhibitor vemurafenib and sensitive to LY3009120, a RAF dimer inhibitor.	LY3009120	181-190	zinc fingers and homeoboxes 2	Homo sapiens	1-4
26732095-6	2016	BRAF homodimer is confirmed to be the dominant RAF dimer by proximity ligation assays in BRAF deletion cells, which are resistant to the BRAF inhibitor vemurafenib and sensitive to LY3009120, a RAF dimer inhibitor.	LY3009120	181-190	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	89-93
26732095-6	2016	BRAF homodimer is confirmed to be the dominant RAF dimer by proximity ligation assays in BRAF deletion cells, which are resistant to the BRAF inhibitor vemurafenib and sensitive to LY3009120, a RAF dimer inhibitor.	LY3009120	181-190	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	89-93
26732095-6	2016	BRAF homodimer is confirmed to be the dominant RAF dimer by proximity ligation assays in BRAF deletion cells, which are resistant to the BRAF inhibitor vemurafenib and sensitive to LY3009120, a RAF dimer inhibitor.	LY3009120	181-190	zinc fingers and homeoboxes 2	Homo sapiens	47-50
26732095-7	2016	In tumor models with BRAF deletions, LY3009120 has shown tumor growth regression, whereas vemurafenib is inactive.	LY3009120	37-46	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	21-25
26732095-9	2016	LY3009120 is active against these cells and represents a potential treatment option for patients with cancer with these BRAF deletions, or other atypical BRAF mutations where BRAF functions as a dimer.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	120-124
26732095-9	2016	LY3009120 is active against these cells and represents a potential treatment option for patients with cancer with these BRAF deletions, or other atypical BRAF mutations where BRAF functions as a dimer.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	154-158
26732095-9	2016	LY3009120 is active against these cells and represents a potential treatment option for patients with cancer with these BRAF deletions, or other atypical BRAF mutations where BRAF functions as a dimer.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	154-158
26343583-0	2015	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.	LY3009120	48-57	zinc fingers and homeoboxes 2	Homo sapiens	14-17
26343583-0	2015	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.	LY3009120	48-57	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	99-103
26343583-1	2015	LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	19-22
26343583-1	2015	LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	27-30
26343583-1	2015	LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	27-30
26343583-1	2015	LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.	LY3009120	0-9	zinc fingers and homeoboxes 2	Homo sapiens	27-30
26343583-2	2015	Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.	LY3009120	48-57	A-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	67-71
26343583-2	2015	Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.	LY3009120	48-57	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	73-77
26343583-2	2015	Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.	LY3009120	48-57	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	83-87
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	18-22
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	23-27
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	88-91
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	mitogen-activated protein kinase 1	Homo sapiens	96-99
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	164-168
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	169-173
26343583-4	2015	Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.	LY3009120	35-44	zinc fingers and homeoboxes 2	Homo sapiens	76-79
26343583-4	2015	Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.	LY3009120	35-44	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	97-101
26343583-4	2015	Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.	LY3009120	35-44	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	105-109
26343583-5	2015	Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.	LY3009120	32-41	mitogen-activated protein kinase kinase 1	Homo sapiens	96-102
26343583-5	2015	Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.	LY3009120	32-41	KRAS proto-oncogene, GTPase	Homo sapiens	187-191
26343583-5	2015	Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.	LY3009120	32-41	NRAS proto-oncogene, GTPase	Homo sapiens	193-197
26343583-5	2015	Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.	LY3009120	32-41	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	202-206